Molecular and clinical risk factors for recurrence of skull base chordomas: Gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 9, 2013, Pages 814-821

  Kitamura, Yohei ^a   Sasaki, Hikaru ^a   Kimura, Tokuhiro ^a   Miwa, Tomoru ^a   Takahashi, Satoshi ^a   Kawase, Takeshi ^a   Yoshida, Kazunari ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brachyury; Chromosome 2p; Comparative genomic hybridization; Fluorescence in situ hybridization; Skull base chordoma; T gene

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CHILD; CHORDOMA; CHROMOSOME 2P; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; HUMAN; IRRADIATION; LOG RANK TEST; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SCHOOL CHILD; SKULL BASE CHORDOMA; SKULL BASE TUMOR; TUMOR RECURRENCE; CHROMOSOME 2; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

BRACHYURY PROTEIN; FETOPROTEIN; T BOX TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; AGED; CHILD; CHORDOMA; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 2; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; FETAL PROTEINS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SKULL BASE NEOPLASMS; T-BOX DOMAIN PROTEINS; YOUNG ADULT;

EID: 84883599418     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182a065d0     Document Type: Article

References (40)

1. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: Incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11
2. The Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 2009; 49(Suppl):1-96
3. CBTRUS. Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007, 2011
4. Favre J, Deruaz JP, Uske A, et al. Skull base chordomas: Presentation of six cases and review of the literature. J Clin Neurosci 1994;1:7-18
5. Takahashi S, Kawase T, Yoshida K, et al. Skull base chordomas: Efficacy of surgery followed by carbon ion radiotherapy. Acta Neurochir (Wien) 2009;151:759-69
6. Bugoci DM, Girvigian MR, Chen JC, et al. Photon-based fractionated stereotactic radiotherapy for postoperative treatment of skull base chordomas. Am J Clin Oncol 2012 [Epub ahead of print]
7. Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 2009;45:2342-51
8. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009;20:1886-94
9. Horbinski C, Oakley GJ, Cieply K, et al. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Pathol Lab Med 2010;134:1170-76
10. Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas: A clinicopathological and prognostic study of 51 cases. J Neurosurg 1993; 78:741-47
11. Jambhekar NA, Rekhi B, Thorat K, et al. Revisiting chordoma with brachyury, a "new age" marker: Analysis of a validation study on 51 cases. Arch Pathol Lab Med 2010;134:1181-87
12. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: A tissue microarrayYbased comparative analysis. Modern Pathol 2008; 21:1461-69
13. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-65
14. Yang XR, Ng D, Alcorta DA, et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 2009;41:1176-78
15. Presneau N, Shalaby A, Ye H, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: A genetic and functional-based study. J Pathol 2011;223:327-35
16. Hsu W, Mohyeldin A, Shah SR, et al. Generation of chordoma cell line JHC7 and the identification of brachyury as a novel molecular target. J Neurosurg 2011;115:760-69
17. Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120:533-44
18. Nelson AC, Pillay N, Henderson S, et al. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol 2012;228:274-85
19. Sasaki H, Yoshida K, Ikeda E, et al. Expression of the neural cell adhesion molecule in astrocytic tumors: An inverse correlation with malignancy. Cancer 1998;82:1921-31
20. Hirose Y, Aldape K, Takahashi M, et al. Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOPPCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 2001;3:62-67
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45
22. Brandal P, Bjerkehagen B,Danielsen H, et al. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet 2005;160:15-21
23. Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001;32:203-11
24. Le LP, Nielsen GP, Rosenberg AE, et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 2011;6:e18846
25. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002;196:194-203
26. Hallor KH, Staaf J, Jonsson G, et al. Frequent deletion of the CDKN2A locus in chordoma: Analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 2008;98:434-42
27. Almefty KK, Pravdenkova S, Sawyer J, et al. Impact of cytogenetic abnormalities on the management of skull base chordomas. J Neurosurg 2009;110:715-24
28. Riva P, Crosti F, Orzan F, et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003; 107:493-97
29. Miozzo M, Dalpra L, Riva P, et al. A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 2000;87:68-72
30. Longoni M, Orzan F, Stroppi M, et al. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol 2008; 10:52-60
31. Sawyer JR, Husain M, Al-Mefty O. Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: A new marker for aggressive tumors? Neurosurg Focus 2001;10:E6
32. Shalaby AA, Presneau N, Idowu BD, et al. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol 2009;22:996-1005
33. Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009; 100:1406-14
34. Chapiro E, Leporrier N, Radford-Weiss I, et al. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res 2010;34:63-68
35. Jarosova M, Urbankova H, Plachy R, et al. Gain of chromosome 2p in chronic lymphocytic leukemia: Significant heterogeneity and a new recurrent dicentric rearrangement. Leuk Lymphoma 2010;51:304-13
36. Beddington RS, Rashbass P, Wilson V. BrachyuryVa gene affecting mouse gastrulation and early organogenesis. Development 1992; 116(Suppl):157-65
37. Edwards YH, Putt W, Lekoape KM, et al. The human homolog T of the mouse T(Brachyury) gene: Gene structure, cDNA sequence, and assignment to chromosome 6q27. Genome Res 1996;6:226-33
38. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 2008;32:572-80
39. al-Mefty O, Borba LA. Skull base chordomas: A management challenge. J Neurosurg 1997;86:182-89
40. Gao Z, Zhang Q, Kong F, et al. Fascin expression in skull base chordoma: Correlation with tumor recurrence and dura erosion. Med Oncol 2012;29:2438-44